Thursday, 5 November 2026European Markets

CONTEXTVISION, EUROFINS SCIENT., Another 1 Companies Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - contextvision (contx.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
contextvision (contx.ol) kr6.80 3.46% 61.1%
eurofins scient. (erf.pa) €54.44 1.85% 9.12%
vetoquinol (veto.pa) €99.20 1.02% 12.13%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. contextvision (contx.ol)

3.46% forward dividend yield and 61.1% return on equity

contextvision ab (publ), a medical technology software company, provides image analysis and imaging for medical systems in asia, europe, and the united states. the company offers image enhancement software for 2d/3d/4d ultrasound, radiography, magnetic resonance imaging (mri), and veterinary. its products include rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; rivent mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and rivent 3d, an image enhancement product for 3d ultrasound. the company also provides altumira/altumira plus, a platform for digital radiography; and orthopedic package for orthopedic imaging. in addition, it offers gopview mri2plus, an image enhancement solution for mri. the company was founded in 1983 and is headquartered in stockholm, sweden.

earnings per share

as for profitability, contextvision has a trailing twelve months eps of kr0.48.

pe ratio

contextvision has a trailing twelve months price to earnings ratio of 14.17. meaning, the purchaser of the share is investing kr14.17 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.

moving average

contextvision's value is way under its 50-day moving average of kr8.37 and way below its 200-day moving average of kr8.72.

more news about contextvision.

2. eurofins scient. (erf.pa)

1.85% forward dividend yield and 9.12% return on equity

eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and technologies services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, eurofins scient. has a trailing twelve months eps of €2.28.

pe ratio

eurofins scient. has a trailing twelve months price to earnings ratio of 23.88. meaning, the purchaser of the share is investing €23.88 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.12%.

more news about eurofins scient..

3. vetoquinol (veto.pa)

1.02% forward dividend yield and 12.13% return on equity

vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.

earnings per share

as for profitability, vetoquinol has a trailing twelve months eps of €4.97.

pe ratio

vetoquinol has a trailing twelve months price to earnings ratio of 19.96. meaning, the purchaser of the share is investing €19.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.

more news about vetoquinol.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com